ANIKライブシグナル | Getagraph.comで利益を最大化

売る 108141 min ago

@ $23.63

発行日: 14 2月 2024 @ 23:30

リターン: 10.28%

前回のシグナル: 2月 13 - 23:30

前回のシグナル: 買う

リターン: 0.60 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:31):

Stats
本日の出来高	14 121.00
平均出来高	80 045.00
時価総額	386.99M
EPS	$0 ( 2024-03-13 )
次の収益日	( $-0.190 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.62
ATR14	$0.0510 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Levitz Michael L	Buy	51 682	Stock Option (Right to Buy)
2024-03-15	Levitz Michael L	Buy	21 329	Restricted Stock Unit
2024-03-15	Colleran David	Buy	46 875	Stock Option (Right to Buy)
2024-03-15	Colleran David	Buy	19 345	Restricted Stock Unit
2024-03-15	Nunes Anne	Buy	26 442	Stock Option (Right to Buy)

INSIDER POWER
51.59
Last 100 transactions
Buy: 1 044 875 \| Sell: 338 384

ボリューム相関

長: 0.05 (neutral)

短: 0.00 (neutral)

Signal:(69.083) Neutral

Anika Therapeutics Inc 相関

10 最も正の相関
RMRM	0.905
BPTH	0.892
GOODN	0.886
RMGC	0.883
MLVF	0.875
BCOV	0.872
ALLT	0.87
WISH	0.868
GOODO	0.868
APTX	0.868

10 最も負の相関
PTRS	-0.908
AAON	-0.874
ULBI	-0.866
CORT	-0.859
PXI	-0.855
STEP	-0.842
PSCE	-0.84
TUR	-0.838
GSHD	-0.837
FTXN	-0.837

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Anika Therapeutics Inc 相関 - 通貨/商品

0.72
( moderate )

0.75
( moderate )

0.00
( neutral )

0.66
( moderate )

-0.27
( neutral )

-0.70
( moderate negative )

Anika Therapeutics Inc 財務諸表

Annual	2023
収益:	$166.66M
総利益:	$103.09M (61.85 %)
EPS:	$-5.64

FY	2023
収益:	$166.66M
総利益:	$103.09M (61.85 %)
EPS:	$-5.64

FY	2022
収益:	$156.24M
総利益:	$93.58M (59.89 %)
EPS:	$-1.020

FY	2021
収益:	$147.79M
総利益:	$82.94M (56.12 %)
EPS:	$0.290

Financial Reports:

No articles found.

Anika Therapeutics Inc

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.